β-Sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma

Journal of Neurobiology

Volumn 39, Issue 3, 1999, Pages 371-382

  Poduslo, Joseph F ^a   Curran, Geoffry L ^a   Kumar, Asok ^b   Frangione, Blas ^b   Soto, Claudio ^b  

^a MAYO CLINIC   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

A fibrillogenesis; Alzheimer's disease; Amyloid peptide (A ); Blood brain barrier; Polyamine modification; Putrescine

Indexed keywords

NEUROPEPTIDE; POLYAMINE; PUTRESCINE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BLOOD BRAIN BARRIER; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; DRUG RESISTANCE; MALE; PEPTIDE HYDROLASES; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033526553     PISSN: 00223034     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4695(19990605)39:3<371::AID-NEU4>3.0.CO;2-E     Document Type: Article

References (36)

1. Blanchard BJ, Konopa G, Russell M, Ingram VM. 1997. Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: relation to Alzheimer's disease. Brain Res 776:40-50.
2. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. 1992. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360:672-674.
3. Citron M, Westaway D, Xia WM, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, Hyslop PS, Selkoe DJ. 1997. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med 3:67-72.
4. Cribbs DH, Pike CJ, Weinstein SL, Velazquez P, Cotman CW. 1997. All-D-enantiomers of β-amyloid exhibit similar biological properties to all-L-β-amyloids. J Biol Chem 272:7431-7436.
5. Fraser PE, McLachlan DR, Surewicz WK, Mizzen CA, Snow AD, Nguyen JT, Kirschner DA. 1994. Conformation and fibrillogenesis of Alzheimer's Aβ peptides with selected substitution of charged residues. J Mol Biol 244:64-73.
6. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagoplan S, Johnson-Wood K, Kan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373:523-527.
7. Golabek A, Soto C, Vogel T, Wisniewski T. 1996. The interaction between Alzheimer β-peptide and apolipoprotein E is dependent on β-peptide conformation. J Biol Chem 271:10602-10606.
8. Herve M, Maillere B, Mourier G, Texier C, Leroy S, Menez A. 1997. On the immunogenic properties of retro-inverso peptides: total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules. J Immunol 156: 157-163.
9. Holcomb L, Gordon M, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo JH, Prada C-M, Eckman C, Younkin KH, Duff K. 1998. Accelerated alzheimer-type phenotype in transgenic mice carrying both mutant amyloid percursor protein and presenilin 1 transgenes. Nat Med 4:97-100.
10. Hsiao KK, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin SG, Yang F, Cole GM. 1996. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
11. Kelly JW. 1996. Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 6:11-17.
12. Ma J, Yee A, Brewer HB Jr, Das S, Potter H. 1994. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372:92-94.
13. Mann DMA, Iwatsubo T, Nochlin D, Sumi SM, Levy-Lahad E, Bird TD. 1997. Amyloid (Aβ) deposition in chromosome 1-linked Alzheimer's disease: the Volga German families. Ann Neurol 41:52-57.
14. Poduslo JF, Low PA, Windebank AJ, Dyck PJ, Berg CT, Schmelzer JD. 1982. Altered blood-nerve barrier in experimental lead neuropathy assessed by changes in endoneurial albumin concentration. J Neurosci 2:1507-1514.
15. Poduslo JF, Curran GL, Dyck PJ. 1988. Increase in albumin IgG and IgM blood-nerve barrier indices in human diabetic neuropathy. Proc Natl Acad Sci USA 85:4879-4883.
16. Poduslo JF, Curran GL. 1992. Increased permeability across the blood-brain barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc Natl Acad Sci USA 89:2218-2222.
17. Poduslo JF, Curran GL, Berg CT. 1994. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci USA 91:5705-5709.
18. Poduslo JF, Curran GL. 1996a. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J Neurochem 66:1599-1609.
19. Poduslo JF, Curran GL. 1996b. Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzimatic activity after covalent modification with the naturally occuring polyamine, putrescine. J Neurochem 67:734-741.
20. Robson B. 1996. Doppelganger proteins as drug leads. Nat Biotechnol 14:893-895.
21. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. 1993. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653.
22. Schumacher TNM, Mayr LM, Minor DL, Mihollen MA, Burgess MW, Kim PS. 1996. Identification of D-peptide ligands through mirror-image phage display. Science 271:1854-1857.
23. Selkoe DJ. 1997. Neuroscience - Alzheimer's disease: genotypes, phenotype, and treatments. Science 275:630-631.
24. Simmons L, May P, Tomaselli K, Rydel R, Fuson K, Brighan E, Wright S, Lieberburg I, Becker G, Brems D, et al. 1994. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 45:373-379.
25. Soto C, Castaño EM, Frangione B, Inestrosa NC. 1995. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem 270:3063-3067.
26. Soto C, Castano E, Kumar R, Beavis R, Frangione B. 1995. Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure. Neurosci Lett 200:105-109.
27. Soto C, Kindy MS, Baumann M, Frangione B. 1996. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem Biophys Res Commun 226:672-680.
28. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castaño EM, Frangione B. 1998. β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4:822-826.
29. Suzuki N, Cheung TT, Cai TT, Cai X-D, Odaka A, Otvos L, Eckman C, Golde TE, Younkin SG. 1994. An increase percentage of long amyloid β protein secreted by familial amyloid β protein precursor (β PP717) mutants. Science 264:1336-1340.
30. Thomas PJ, Qu B-H, Pedersen PL. 1995. Defective protein folding as a basis of human disease. Trends Biochem Sci 20:456-459.
31. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, Terenius L, Nordstedt C. 1996. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271:8545-8548.
32. Tjernberg LO, Lilliehook C, Callaway DJE, Naslund J, Hahne S, Thyberg J, Terenius L, Nordstedt C. 1997. Controlling amyloid β-peptide fibril formation with protease-stable ligands. J Biol Chem 272:12601-12605.
33. Wisniewski KE, Wisniewski HM, Wen GY. 1985. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17: 278-282.
34. Wisniewski T, Castaño EM, Golabek A, Vogel T, Frangione B. 1994. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145:1030-1035.
35. Wisniewski T, Ghiso J, Frangione B. 1994. Alzheimer's disease and soluble Aβ. Neurobiol Aging 15:143-152.
36. Wisniewski, T, Aucouturier, P., Soto, C., Frangione, B. 1998. The prionoses and other conformational disorders. Amyloid 5:212-224.